Summary
68 / 100 · Bulios Score
What speaks for it
- Out of every 100 CNY of revenue, 16 CNY is left as net profit.
- It holds more cash than debt: ¥11.7B against ¥1.20B.
- The share price is below the Bulios Fair Price.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 6.1 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 8.0% a year over 5 years. Over the last 3 years it grew by 4.3% a year. For the next fiscal year analysts expect revenue to fall by 2.8%. Earnings per share grew by 6.5% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CNY of revenue goes
- Cost of sales 69 CNY
- Research and development 3.6 CNY
- Sales and administration 23 CNY
- Taxes and other -0.0 CNY
- Net profit 4.5 CNY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 CNY
Out of every 100 CNY of revenue, 4.5 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.8 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 4.05%
- Paid out of profit
- 25%
- Raised in a row
- 3 years
You receive $0.04 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.